Jazz’ Enrylaze Receives EC’s Approval for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Shots:
- The EC has granted marketing authorization for Enrylaze for use as a component of a multi-agent chemotherapeutic regimen to treat ALL & LBL in adult & pediatric patients aged ≥1mos.
- The approval was based on the P-II/III trial (conducted in collaboration with Children's Oncology Group) evaluating Enrylaze (administered as IV infusions and IM inj.) in 228 pediatric & adult patients, showed that patients treated with JZP458 as IV maintained NSAA ≥0.1 U/mL (89.8%) at 48hrs. after a dose & 40% at 72hrs. post-dose
- The IM administration of JZP458 (25/25/50mg/m2 MWF) achieved sustained asparagine activity in 95.9% at 48hrs. & 89.8% at 72hrs. post-dose. Enrylaze was approved as Rylaze in the US & Canada
Ref: PRNewswire | Image: Jazz Pharmaceuticals
Related News:- Jazz and Zymeworks Present P-IIb Trial (HERIZON-BTC-01) Results of Zanidatamab for HER2-Amplified Biliary Tract Cancers at ASCO 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.co
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
